Treatment Experienced: Suppressed


A5315: A Phase I/II Study of Single Dose Romidepsin in HIV-Infected Adults with Suppressed Viremia on Antiretroviral Therapy to Assess Safety, Tolerability, and Activation of HIV-1 Expression

A5324: A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with No Intesification or Intesification with Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV

A5332: REPRIEVE - Randomized Trial to Prevent Vascular Events in HIV

A5337:  A Phase I/II, Open Label, Single Arm, Pilot Study to Evaluate the Safety of Sirolimus and its Efficacy with Respect to its Effects on HIV-1 Reservoir Size and Immune Function

ATLAS:  A Phase III, randomized, multicenter, parallel-group, non-inferiority, open-label study evaluating the efficacy, safety, and tolerability of switching to long-acting cabotegravir plus long-acting rilpivirine from current INI- NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed

CID 0819:  A pheresis Procedures to Obtain Leukocytes from HIV+ Subjects

IGHD 11424 - The VOR VAX Study: The Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection

IRB 15-2865: Antiretroviral Localization in the Gut-Associated Lymphoid Tissue and Lower Female Genital Tract Tissue of HIV+ Subjects


BMA: Role of Macrophage Cells in HIV Latency in the Bone Marrow


XTRA Study: A Phase I Study to Evaluate the Effects of Vorinostat and HIV-1 Antigen Expanded Specific T-Cell Therapy (HXTC) on Persistent HIV-1 Infection HIV-Infected Individuals Started on Antiretroviral Therapy

20, HIV-1 infected patients > 18 years of age with undetectable viral load and CD4 count > 300; no known cardiac hx or known resistance to ≥ 2 classes of drugs.